trial summary · NCT05555550
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
Evaluation of 18F-Fluciclovine PET-MRI as a Biomarker of Response in Pediatric and Young Adult Patients With Low Grade Gliomas (LGG)
Trial record from the TrialBase DB dataset, status RECRUITING, condition Glioma, sponsored by Children's Hospital of Philadelphia. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The purpose of this study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the management of children with Low Grade Gliomas (LGG). Imaging with 18F-Fluciclovine PET-MRI will be performed prior to initiation of therapy for LGG, and then 3 months, and 1 year after starting therapy. Changes in 18F-Fluciclovine uptake will be compared to changes in MRI measurements at 3 months and 1 year as compared to baseline.
Source record: https://clinicaltrials.gov/study/NCT05555550
Facts
| registry id | NCT05555550 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | EARLY_PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | Glioma |
| sponsor | Children's Hospital of Philadelphia |
| sponsor class | OTHER |
| enrollment | 30 |
| start date | 2026-11-29 |
| primary completion | 2027-12 |
| completion | 2028-09 |
| results posted | not reported |
Conditions
- Glioma
- Low-grade Glioma
- Low Grade Glioma of Brain
- Glioma, Malignant
- Glioma Intracranial
Interventions
- 18F-Fluciclovine
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.